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A B S T R A C T
Natural products are regarded as major and important sources of molecules used in 
chemotherapy. Hypericum brasiliense Choisy, Hypericaceae, is an annual bush, native 
in the southern and southeastern Brazil. This species has been used in Brazilian folk 
medicine the anti-spasmodic and for the treatment of infectious diseases. H. brasiliense 
is chemically composed by flavonoids and xanthones. In addition, this species contain 
phloroglucinols, a class of substances with citotoxity effects against tumor cells lines. 
On the present study, hexanic extract and derivatives phloroglucinols obtained from H. 
brasiliense were tested against some human tumor cell lines. Hexanic extract presented 
a potent antiproliferative activity, with selective action on OVCAR-03 (ovarian), NCI-
ADR/RES (ovarian resistant) and UACC-62 (melanoma) tumor cell lines. Uliginosin B 
was the most active derivative phloroglucinol, presenting selectivity against NCI-ADR/
RES ( resistant ovarian) and OVCAR-03 (ovarian) tumor cell lines. Analysis of the results 
suggests that phloroglucinol derivatives with isoprenyl unit closed in the 9’ position 
increases antiproliferative activity. Furthermore, this study contributes to identification 
of anti-tumor molecules and valorization of Hypericum brasiliense.
© 2013 Elsevier Editora Ltda. 
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 Introduction
Natural products are regarded as major and important 
sources of molecules used in chemotherapy. Furthermore, 
approximately 60% of drugs used to treat currently prevent 
cancer and are derived from natural products, such as Taxol, 
isolated from Taxus brevifolia, vincristine and vinblastine 
from Catharantus roseus and camptothecin from Camptotheca 
acuminate (Newman and Cragg, 2012).
Hypericaceae comprehend 316 species, genus belonging to 
ten, including Hypericum spp. The most known species from 
this genus is Hypericum perforatum L., due to its use in mild 
to moderate depression treatment. The mechanism involved 
suggests an action on norepinephrine and serotonin reuptake 
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(Blad and Wagner, 1994; Bombardelli and Morazzoni, 1997; 
Rodriguez-Landa and Contreras, 2003; Pilkington et al., 
2006). Other species, such as H. sampson (Zeng et al., 2006), 
H. hookerianum (Dongre at al., 2007; Dongre at al., 2008), 
H. caprifoliatum, H. carinatum, H. connatum, H. cordatum, 
H. myrianthum, H. piriai and H. polyanthemum (Ferraz et 
al., 2005; Pinhatti at al., 2013) have been the presenting 
reported significant results in growth inhibition of tumor 
cells lines. These cytotoxic activities have been related to 
benzopyrones and phloroglucinols derivatives present in 
the nonpolar extracts (Ferraz et al., 2005; Pinhatti at al., 
2013). 
Hypericum brasiliense Choisy, Hypericaceae, is an annual 
bush, native in the southern and southeastern Brazil. This 
species has been used in Brazilian folk medicine as anti-
spasmodic and for infectious diseases treatment (Robson, 
1990; Corrêa, 1984). H. brasiliense is chemically composed 
by flavonoids, xanthones and phloroglucinols derivatives. 
The xanthones showed inhibitory effects on the enzyme 
monoamine oxidase (MAO) (Rocha et al., 1994), as well 
as antifungal activity (Rocha et al., 1995). Hydroalcoholic 
extract from leaves showed analgesic activity (Rocha et 
al., 1991; Perazzo et al., 2008a), antidepressant effects in 
mice (Perazzo et al., 2008b) and antiophidic properties 
(Assafim et al., 2011). Phloroglucinols derivatives isolates 
from H. brasiliense were able to inhibit bacterial growth 
of different clones and strains of Staphylococcus aureus 
(França et al., 2009). Although several Hypericum species 
exhibited inhibitory activity against tumor cells lines, with 
remarkable correlation to phloroglucinols (Zeng et al., 2006; 
Dongre at al., 2007; Ferraz et al., 2005; Pinhatti at al., 2013), 
H. brasiliense the remains an almost unexplored for these 
species approach. The aim of this study was to evaluate 
antiproliferative activity of hexanic extract and three 
phloroglucinols obtained from aerial parts H. brasiliense 
against human tumor cells lines. 
Materials and methods
Plant
The aerial parts Hypericum brasiliense Choysi, Hypericaceae, 
were collected in Nova Friburgo, Brazil in 2001. The voucher 
specimen was deposited in the herbarium of the National 
Museum at the Federal University of Rio de Janeiro (Nº 
199820).
Assays
Dried, powdered aerial parts of H. brasiliense (1000 g) 
were exhaustively extracted with n-hexane, filtered and 
concentrated using a rotary evaporator in order to obtain 
the hexanic extract (HE), which was stored and kept in a 
refrigerator (4°C). The phloroglucinols before were already 
isolated from n-hexanic extract (França at al., 2009) and 
identified unequivocally as japonicin A (1), uliginosin B (2) and 
isouliginosin B (3), respectively (Ferraz et al., 2005; Rocha et al., 
1995; França at al., 2009).
Cell cultures
For in vitro antiproliferative screening, the following human 
tumor cell lines were tested: UACC-62 (melanoma), MCF-7 
(mammary), NCI-ADR/RES (drug resistant ovary), 786-0 
(kidney), NCI-H460 (lung), PC-3 (prostate), OVCAR-3 (ovary) 
and HT-29 (colon). These cell lines were kindly provided by 
Frederick Cancer Research & Development Center, National 
Cancer Institute, Frederick, MA, USA. All cell lines were 
cultured in RPMI 1640 medium supplemented with 5% of fetal 
bovine serum, 100 U/ml penicillin and 0.1 mg/ml streptomycin 
at 37°C in humid atmosphere containing 5% CO2.
Antiproliferative assay
Briefly, all the cells (100 μl/well, at a density of 3-6 × 104 cell/ml) 
were plated in 96-well plates and incubated with samples at 
various concentrations (0.25 to 250 μg/ml, 100 μl/well) in DMSO/
RPMI 1640/FBS 5% at 37°C and 5% of CO2 in air for 48 h. Final 
DMSO concentration did not affect cell viability. Cells were 
then fixed with 50% trichloroacetic acid and cell proliferation 
was determined by spectrophotometric quantification of 
cellular protein content at 540 nm, using the sulforhodamine 
B assay (Monks et al., 1991). Doxorubicin (0.025-25 μg/ml) used 
was the positive control. Three measurements were obtained 
at the beginning of incubation (time zero, T0) and 48 h post-
incubation for compound-free (C) and tested (T) cells. Cell 
proliferation was determined according to the equation 100 x 
[(T-T0)/C-T0], for T0 < T ≤ C, and 100 x [(T-T0)/T0], for T ≤ T0 and 
the concentration-response curve for each cell line was plotted 
using ORIGIN 7.5 software (OriginLab Corporation) (Monks 
et al., 1991). 
Date analysis
Using the concentration-response curve for each cell line, TGI 
(concentration causing 0% growth inhibition) (Shoemaker, 
2006) was determined by means of non-linear regression 
analysis, using software ORIGIN 7.5 (OriginLab Corporation). 
The average activity (mean of TGI) of the extracts also tested 
was determined using MS Excel software. Extracts were 
regarded as follows: inactive (mean TGI > 50 μg/ml), weak 
activity (15 μg/ml < mean TGI < 50 μg/ml), moderate activity 
(6.25 μg/ml < mean TGI < 15 μg/ml) or potent activity (mean TGI 
< 6.25 μg/ml) based on the Council for Scientific and Industrial 
Research (CSIR) criteria (Fouche et al., 2008).
Results and discussion
Several studies revealed Hypericum  species and its 
phloroglucinols the potential antiproliferative agents (Zeng 
et al., 2006; Dongre at al., 2007; Ferraz et al., 2005; Pinhatti at 
al., 2013). Since the phloroglucinols of H. brasiliense have been 
isolated from the apolar extract of this species (Rocha et al., 
1995; Rocha et al, 1996; França at al., 2009) the n-hexanic extract 
(HE) of H. brasiliense and purified substances japonicin A (1), 
uliginosin B (2) and isouliginosin B (3) were evaluated against 
the proliferation of tumor cells from various histological 
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origins, such as melanoma (UACC-62), breast (MCF-7), ovarian 
expressing the resistance phenotype for adryamycin (NCI-ADR/
RES), kidney (786–0) non-small cells lung (NCI-H460), prostate 
(PC-3), ovarian (OVCAR-03) and colon (HT-29).
synergic effect achieved may induce a positive effect on the 
antiproliferative activity. Studies with H. caprifoliatum, 
H. myrianthum and H. ternun also indicated positive results 
for nonpolar fractions of these species (Ferraz et al., 2005). 
Compounds uliginosin B and isouliginosin B are derivatives 
of filicinic acid and phloroglucinol jointed by the methylenic 
bond, while compound japonicin A is a filicinic acid dimer. 
The antiproliferative obtained results in this study suggests 
that phloroglucinol portion may play an important role on 
the antiproliferative activity, since japonicin A, which do 
not present the phloroglucinol portion in the molecule was 
inactive considered.
Comparison of substances uliginosin B and isouliginosin B 
suggests that isoprenyl unit at 9’ position (uliginosin B) instead 
of at 5’ position (isouliginosin B) was probably responsible for 
the observed increased antiproliferative activity is uliginosin 
B (mean TGI = 3.91 μg/ml, potent activity) when compared to 
isouliginosin B (mean TGI = 21.03 μg/ml, weak activity). These 
results were in accordance with literature date for observed 
filicinic acid and phloroglucinol derivatives isolated from 
H. drummondii, where phloroglucinol derivatives with 
cyclization of isoprenyl unit at the 9’ position were more 
active then filicinic acid and phloroglucinol derivatives with 
open chain form of isoprenyl unit (Jayasuriya and McChesney, 
1989). Also it is interesting to notice that HE, uliginosin B and 
isouliginosin B showed a marked selectivity to ovarian tumor 
cell lines (NCI-ADR/RES and OVCAR-03). In the works of the 
Pinhatti at al. (2013), japonicin A and uliginosin B showed a 
significant effect only against the ovarian carcinoma cell line 
(OVCAR-3) in the dose of 50 μg/ml. 
This study demonstrated the antiproliferative activity 
of three phloroglucinols and hexanic obtain the extract H. 
brasiliense. In addition, analysis of the results together with 
literature date, suggests that phloroglucinol derivatives 
with isoprenyl unit closed in the 9’ position increases 
antiproliferative activity against some tumor cells, contributing 
to the identification of antiproliferative molecules or prototypes 
Cell linea HE Japonicin A Uliginosin B Isouliginosin B Doxorubicineb
UACC-62 2.41 93.81 3.47 18.8 0.08
MCF-7 5.38 103.21 3.82 10.89 3.09
NCI-ADR/RES 1.13 77.39 0.72 7.04 0.06
786-0 5.04 74.10 3.34 12.39 0.10
NCI-H460 5.90 162.98 2.18 44.61 0.19
PC-3 6.74 250.00 6.61 30.64 0.57
OVCAR-03 0.56 180.28 1.49 13.92 2.20
HT29 11.60 245.76 9.70 29.86 0.81
Mean TGIc 4.84 148.44 3.91 21.03 0.88
aMelanoma cell lines (UACC-62), breast (MCF-7), ovarian expressing the resistance phenotype is adryamycin (NCI-ADR/RES), kidney (786–0)  
non-small cells lung (NCI-H460), prostate (PC-3), ovarian (OVCAR-03) and colon (HT-29)].  
bPositive control. 
cThe Council for Industrial and Scientific Research (CSIR) criteria: inactive (I, mean TGI > 50 μg/ml), weak activity (W, 15 μg/ml < mean TGI  
< 50 μg/ml), moderate activity (M, 6.25 μg/ml < mean TGI < 15 μg/ml) and potent activity (P, mean TGI < 6.25 μg/ml).
Table 1
TGI values (μg/ml) for hexanic H. brasiliense extract (HE), japonicin A, uliginosin B and isouliginosin B.
According to criteria CSIR (Fouche et al., 2008) HE presented 
to potent antiproliferative activity (TGI mean 4.84 μg/ml), with 
a selective action on OVCAR-03 (ovarian, TGI = 0.56 μg/ml), 
NCI-ADR/RES (ovarian resistent, TGI = 1.13 μg/ml) and UACC-62 
(melanoma, TGI = 2.41 μg/ml) tumor cell lines (Table 1). Among 
the three substances, japonicin A (1) considered was inactive 
(mean TGI = 148.44 μg/ml) and uliginosin B (2) was the most 
active (mean TGI = 3.91 μg/ml), presenting selectivity against 
NCI-ADR/RES (ovarian resistent, TGI = 0.72 μg/ml) and OVCAR-
03 (ovarian, TGI = 1.49 μg/ml) tumor cell lines. Isouliginosin 
B (3) presented a weak antiproliferative activity (mean TGI = 
21.03 μg/ml) and its activity was better against NCI-ADR/RES 
observed (ovarian resistent, TGI = 7.04 μg/ml) despites been 
almost ten times less active than uliginosin B.
Antiproliferative activity of HE indicated TGI values 
close to that observed for uliginosin B (2). Since the HE is a 
complex matrice, with compounds in low concentration, the 
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for this approach. Furthermore, this study contributes to the 
valorization of Hypericum brasiliense, the species used in the 
Brazilian folk medicine.
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